The expansion into Silicon Valley marks a strategic move for Ajinomoto Co., which seeks to support and collaborate with innovators across four key growth a...
Takeda unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...
Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...
Meningitis, characterized by inflammation of the protective membranes enveloping the brain and spinal cord, poses a grave medical emergency due to ...
Amit Chopra, a seasoned professional with a proven track record in leadership, commercial strategies, manufacturing, mergers and acquisitions, and innovati...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East...
Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
Travere Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endot...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
Embracing the latest technology trends, LPH 1.0 represents a significant leap forward, with an upgrade to HTML5 browser-based technology. This advancement ...
© 2025 Biopharma Boardroom. All Rights Reserved.
